Evidence map›Paper›PMID 33054124›Full record

ArticleHaematologica2020

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.

Nadia Peragine, Maria Stefania De Propris, Stefania Intoppa, Maria Laura Milani, Paola Mariglia, Francesca Romana Mauro, Sara Raponi, Stefano Soddu, Antonio Cuneo, Gian Matteo Rigolin and 3 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Nadia PeragineHematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome.
Maria Stefania De ProprisHematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome.
Stefania IntoppaHematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome.
Maria Laura MilaniHematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome.
Paola MarigliaHematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome.
Francesca Romana MauroHematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome.
Sara RaponiHematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome.
Stefano SodduItalian Group for Adult Hematologic Diseases (GIMEMA) Foundation, Rome.
Antonio CuneoHematology, Department of Medical Sciences, University of Ferrara, Ferrara.
Gian Matteo RigolinHematology, Department of Medical Sciences, University of Ferrara, Ferrara.
Ilaria Del GiudiceHematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome.
Robin FoàHematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome . rfoa@bce.uniroma1.it.
Anna GuariniDepartment of Molecular Medicine, "Sapienza" University, Rome, Italy.
Sapienza University of Rome · ITUniversity of Ferrara · ITFondazione Gimema Onlus · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellAdenineAntineoplastic Combined Chemotherapy ProtocolsHumansPiperidinesPyrazolesPyrimidinesRituximabTreatment OutcomeAdenineibrutinibPiperidinesPyrazolesPyrimidinesRituximab

Identifiers

PMID33054124
PMCPMC8094098
OpenAlexW3092119415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.